Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 162 participants.

Also called NCT07687212

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 162 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07687212
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07687212. Randomized; quadruple masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
Condition
Heart Failure, Preserved Ejection Fraction
Intervention (Drug)
Henggliflozin Combined with Probiotics
Intervention (Drug)
Henggliflozin
Intervention (Drug)
double placebo
Lead sponsor
The First Affiliated Hospital of Air Force Medical University (class: other)

Record details

Record id
cardio:ct-nct07687212
Content hash
8c48379cf94ff44c8ed3dccdc27b34ae46c0ced728518981a103fa8a3eb098b6